The Trump administration is defending a Biden-era decision to reject drug manufacturer plans that would allow them to discount medicines through a rebate rather than up front under a federal drug discount program. HRSA on Monday doubled down on its argument that implementing a rebate model is inconsistent with the 340B statute and requires approval from the HHS secretary. The agency, however, signaled that it could be open to further consideration of the plan.
